On September 9, 2017, Rani Therapeutics, LLC closed the transaction. The company has received $38,663,952 in funding from 12 investors pursuant to Regulation D. The company has raised $100 million in funding so far in the transaction. The transaction included participation from Novartis AG (SWX:NOVN) and AstraZeneca PLC (LSE:AZN).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.37 USD | 0.00% | -2.90% | +91.87% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
12,128 GBX | -0.23% | +7.51% | 235B | ||
113.1 CNY | -1.20% | +2.41% | 6.28B | ||
88.56 CHF | -0.35% | -0.43% | 199B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.87% | 168M | |
-1.65% | 103B | |
+6.75% | 101B | |
+6.70% | 23.07B | |
-12.60% | 22.23B | |
-5.24% | 18.05B | |
-39.98% | 17.18B | |
-10.17% | 16.94B | |
+6.12% | 14.07B | |
+35.47% | 12.35B |
- Stock Market
- Equities
- RANI Stock
- News Rani Therapeutics Holdings, Inc.
- Rani Therapeutics, LLC announced that it has received $38.663952 million in funding from a group of investors